Evidence map›Paper›PMID 30816326›Full record

ArticleScientific reports2019

GPDPLQ

Henrik Löfvall, Anna Katri, Aneta Dąbrowska, Morten A Karsdal, Yunyun Luo, Yi He, Tina Manon-Jensen, Morten H Dziegiel, Anne-Christine Bay-Jensen, Christian S Thudium and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Henrik LöfvallNordic Bioscience, Herlev, Denmark.
Anna KatriNordic Bioscience, Herlev, Denmark.
Aneta DąbrowskaNordic Bioscience, Herlev, Denmark.
Morten A KarsdalNordic Bioscience, Herlev, Denmark.
Yunyun LuoNordic Bioscience, Herlev, Denmark.
Yi HeNordic Bioscience, Herlev, Denmark.
Tina Manon-JensenNordic Bioscience, Herlev, Denmark.
Morten H DziegielDepartment of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Anne-Christine Bay-JensenNordic Bioscience, Herlev, Denmark.
Christian S ThudiumNordic Bioscience, Herlev, Denmark.
Kim HenriksenNordic Bioscience, Herlev, Denmark. kh@nordicbio.com.
Nordic Bioscience (Denmark) · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C-telopeptide of type II collagen (CTX-II) has been shown to be a highly relevant biomarker of cartilage degradation in human rheumatic diseases, if measured in synovial fluid or urine. However, serum or plasma CTX-II have not been demonstrated to have any clinical utility to date. Here, we describe the GPDPLQ

Indexed as

AnimalsArthritis, ExperimentalCartilage, ArticularCattleCollagen Type IICysteine ProteasesCysteine Proteinase InhibitorsDipeptidesEnzyme-Linked Immunosorbent AssayEpitopesFreund's AdjuvantHumansLimit of DetectionMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMicecollagen II C-telopeptideCollagen Type IICysteine ProteasesCysteine Proteinase InhibitorsDipeptidesEpitopesFreund's AdjuvantMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamidePeptide Fragments

Identifiers

PMID30816326
PMCPMC6395810
OpenAlexW2915568454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.